You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER2-positive metastatic Breast Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Breast Cancer Trial (BDC-1001, Pertuzumab)

Not yet recruiting
  • Metastatic Breast Cancer
  • (no location specified)
Jul 12, 2023

Breast Cancer Trial in Xi'an (Inetetamab plus pyrotiniband and capecitabine)

Active, not recruiting
  • Breast Cancer
  • Inetetamab plus pyrotiniband and capecitabine
  • Xi'an, Shaanxi, China
    Xi'an International Medical Center Hospital
Aug 27, 2023

Breast Cancer Trial in Nanjing (Inetetamab, Pyrotinib, Oral Vinorelbine Tartrate)

Recruiting
  • Breast Cancer
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital with Nanjing Medical University
Apr 10, 2023

HER2-positive Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Miami (Discontinuation of Anti-HER-2 Maintenance

Recruiting
  • HER2-positive Metastatic Breast Cancer
  • Stage IV Breast Cancer
  • Discontinuation of Anti-HER-2 Maintenance Treatment
  • Miami, Florida
    University of Miami
Jul 17, 2023

Advanced/ Metastatic Her-2 Positive Breast Cancer Trial in Shanghai (GQ1001+pyrotinib, pyrotinib+capecitabine)

Active, not recruiting
  • Advanced/ Metastatic Her-2 Positive Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 15, 2022

Inetetamab Combined With Pyrotinib and Vinorelbine as First-line

Recruiting
  • Breast Neoplasms
  • Nanjing, Jiangsu, China
    Jiangsu Provincial People's Hospital
Mar 16, 2023

Breast Cancer Trial in Shanghai (Dalpiciclib, Fulvestrant, Pertuzumab)

Active, not recruiting
  • Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Oct 10, 2022

HER2-positive Recurrent/Metastatic Breast Cancer Trial (Inetetamab, pyrotinib, chemo)

Not yet recruiting
  • HER2-positive Recurrent/Metastatic Breast Cancer
  • Inetetamab, pyrotinib, chemotherapy
  • (no location specified)
Nov 16, 2022

Metastatic Breast Cancer, Advanced Breast Cancer, HER2-positive Breast Cancer Trial (Margetuximab, Tucatinib, Capecitabine)

Withdrawn
  • Metastatic Breast Cancer
  • +2 more
  • (no location specified)
Jul 6, 2022

HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy Trial (Trastuzumab Emtansine for Injection, Pyrotinib Maleate

Not yet recruiting
  • HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy
  • Trastuzumab Emtansine for Injection
  • Pyrotinib Maleate Tablets
  • (no location specified)
Sep 30, 2022

HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer Trial in Chicago, Minneapolis (ALX148, Fam-Trastuzumab

Recruiting
  • HER2-positive Breast Cancer
  • +17 more
  • ALX148
  • Fam-Trastuzumab Deruxtecan-Nxki
  • Chicago, Illinois
  • +1 more
May 19, 2023

Breast Cancer Trial in Beijing (QL1701, Herceptin®, Docetaxel)

Active, not recruiting
  • Breast Cancer
  • Beijing, China
    Cancer Hospital,Chinese Academy of Medical Sciences
Nov 18, 2022

HER2-positive Metastatic Breast Cancer Trial in Aurora, Madison (Alpelisib, Tucatinib, Fulvestrant)

Recruiting
  • HER2-positive Metastatic Breast Cancer
  • Aurora, Colorado
  • +2 more
Dec 29, 2022

HER2-positive Breast Cancer, Metastatic Breast Cancer Trial in Shanghai (Trastuzumab plus chemo, Trastuzumab in combination with

Recruiting
  • HER2-positive Breast Cancer
  • Metastatic Breast Cancer
  • Trastuzumab plus chemotherapy
  • Trastuzumab in combination with pyrotinib plus chemotherapy
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 20, 2022

HER2 Positive Metastatic Breast Cancer Trial in Beijing (pyrotinib, , Capecitabine)

Active, not recruiting
  • HER2 Positive Metastatic Breast Cancer
  • Beijing, China
    307 Hospital Affiliated to Academy Military Medical Science
Oct 24, 2022

HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer Trial in Germany, Spain,

Recruiting
  • HER2-positive Breast Cancer
  • +4 more
  • Essen, Germany
  • +5 more
Nov 15, 2022

HER2 Positive Metastatic Breast Cancer Trial in Zhengzhou (Pyrotinib plus Capecitabine)

Active, not recruiting
  • HER2 Positive Metastatic Breast Cancer
  • Pyrotinib plus Capecitabine
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Dec 9, 2021

HER2 Positive Metastatic Breast Cancer Trial in Zhengzhou (inetetamab and PD-1 inhibitor combined with chemo.)

Recruiting
  • HER2 Positive Metastatic Breast Cancer
  • inetetamab and PD-1 inhibitor combined with chemotherapy.
  • Zhengzhou, Henan, China
    Henan cancer hospital
Aug 2, 2022

HER2-positive Breast Cancer Trial in Shanghai (68Ga/131I-SGMIB-5F7)

Not yet recruiting
  • HER2-positive Breast Cancer
  • 68Ga/131I-SGMIB-5F7
  • Shanghai, China
    Huashan Hospital
Aug 1, 2023

HER2-positive Breast Cancer Trial in Amsterdam (Trastuzumab deruxtecan)

Not yet recruiting
  • HER2-positive Breast Cancer
  • Trastuzumab deruxtecan
  • Amsterdam, Netherlands
    Antoni van Leeuwenhoek
Aug 7, 2023

HER2-positive Breast Cancer Trial (Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab))

Not yet recruiting
  • HER2-positive Breast Cancer
  • Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab)
  • (no location specified)
Jul 20, 2023

HER2 Mutant NSCLC, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation Trial (ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki,

Not yet recruiting
  • HER2 Mutant Non-small Cell Lung Cancer
  • +3 more
  • (no location specified)
Dec 6, 2022

HER2-PositiveRecurrent or Metastatic Breast Cancer Trial (SHR-A1811 Injection, SHR-A1811 Injection ; Pertuzumab Injection,

Not yet recruiting
  • HER2-PositiveRecurrent or Metastatic Breast Cancer
  • SHR-A1811 Injection
  • +2 more
  • (no location specified)
Sep 21, 2023

Tyrosine Kinase Inhibitors in Trastuzumab Emtansine Resistant

Recruiting
  • Breast Cancer
  • Nanjing, Jiangsu, China
    Jiangsu Provincial People's Hospital
Feb 7, 2022

Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer Trial in Boston (Cessation of anti-HER2 treatment)

Not yet recruiting
  • Breast Cancer
  • +2 more
  • Cessation of anti-HER2 treatment
  • Boston, Massachusetts
  • +1 more
Feb 9, 2023